Article
Genetics & Heredity
Mathias Schwartz, Sabrina Ibadioune, Albain Chansavang, Sophie Vacher, Sandrine M. Caputo, Helene Delhomelle, Jennifer Wong, Khadija Abidallah, Virginie Moncoutier, Veronique Becette, Tatiana Popova, Voreak Suybeng, Antoine De Pauw, Marc-Henri Stern, Chrystelle Colas, Emmanuelle Mouret-Fourme, Dominique Stoppa-Lyonnet, Lisa Golmard, Ivan Bieche, Julien Masliah-Planchon
Summary: Mosaic BRCA1 promoter methylation is associated with an increased risk of early-onset breast cancer, triple-negative breast cancer, and ovarian cancer. This de novo event could contribute to hereditary breast/ovarian cancer pedigrees, especially in families with affected relatives showing high prevalence of BRCA1meth. Detection of BRCA1meth may indicate involvement of BRCA1 in tumorigenesis in affected probands.
JOURNAL OF MEDICAL GENETICS
(2023)
Article
Oncology
Per E. Lonning, Oleksii Nikolaienko, Kathy Pan, Allison W. Kurian, Hans P. Eikesdal, Mary Pettinger, Garnet L. Anderson, Ross L. Prentice, Rowan T. Chlebowski, Stian Knappskog
Summary: This study found a significant association between constitutional normal tissue BRCA1 promoter methylation and the risk of developing triple-negative breast cancer (TNBC) and high-grade serous ovarian cancer (HGSOC).
Review
Oncology
Ilary Ruscito, Maria Luisa Gasparri, Maria Paola De Marco, Flavia Costanzi, Aris Raad Besharat, Andrea Papadia, Thorsten Kuehn, Oreste Davide Gentilini, Filippo Bellati, Donatella Caserta
Summary: This meta-analysis aimed to analyze the clinical characteristics of breast cancer with BRCA1 gene hypermethylation. Results showed a strong correlation between BRCA1 hypermethylation and advanced breast cancer stage, lymph node involvement, and premenopausal status. This suggests the potential for personalized treatment strategies for this subgroup of breast cancer patients.
Article
Oncology
M. J. M. Magbanua, L. B. Swigart, H-T Wu, G. L. Hirst, C. Yau, D. M. Wolf, A. Tin, R. Salari, S. Shchegrova, H. Pawar, A. L. Delson, A. DeMichele, M. C. Liu, A. J. Chien, D. Tripathy, S. Asare, C-H J. Lin, P. Billings, A. Aleshin, H. Sethi, M. Louie, B. Zimmermann, L. J. Esserman, L. J. van 't Veer
Summary: The study investigated the utility of serial ctDNA testing in predicting pCR and risk of metastatic recurrence during neoadjuvant chemotherapy for high-risk early breast cancer patients. The results showed that lack of ctDNA clearance was a significant predictor of poor response and metastatic recurrence, while clearance was associated with improved survival even in patients who did not achieve pCR. Personalized monitoring of ctDNA during NAC may aid in real-time assessment of treatment response and help fine-tune pCR as a surrogate endpoint of survival.
ANNALS OF ONCOLOGY
(2021)
Review
Oncology
Mira Shoukry, Sacha Broccard, Jamie Kaplan, Emmanuel Gabriel
Summary: As breast cancer diagnoses continue to increase globally, exploring the role of liquid biopsies and circulating tumor DNA (ctDNA) in diagnosis and surveillance becomes increasingly important. CtDNA is emerging as a potential biomarker for breast cancer, offering personalized and effective treatment approaches.
Article
Oncology
Katrina Cristall, Francois-Clement Bidard, Jean-Yves Pierga, Michael J. Rauh, Tatiana Popova, Clara Sebbag, Olivier Lantz, Marc-Henri Stern, Christopher R. Mueller
Summary: mDETECT is a next-generation sequencing-based blood test designed for the optimal detection and monitoring of metastatic triple-negative breast cancer. It offers superior performance, high sensitivity, and specificity in detecting TNBC, providing potential improvements in patient management.
NPJ PRECISION ONCOLOGY
(2021)
Article
Medicine, General & Internal
Andrew N. J. Tutt, Judy E. Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmana, Susan M. Domchek, Karen A. Gelmon, Simon J. Hollingsworth, Larissa A. Korde, Barbro Linderholm, Hanna Bandos, E. Senkus, Jennifer M. Suga, Z. Shao, Andrew W. Pippas, Zbigniew Nowecki, Tomasz Huzarski, Patricia A. Ganz, Peter C. Lucas, Nigel Baker, Sibylle Loibl, Robin McConnell, Martine Piccart, Rita Schmutzler, Guenther G. Steger, Joseph P. Costantino, Amal Arahmani, Norman Wolmark, Eleanor McFadden, Vassiliki Karantza, Sunil R. Lakhani, Greg Yothers, Christine Campbell, Charles E. Geyer
Summary: In patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than placebo. Olaparib had limited effects on global patient-reported quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Zainab Lafi, Walhan Alshaer, Lobna Gharaibeh, Dana A. Alqudah, Baidaa Alquaissi, Banan Bashaireh, Abed Alqader Ibrahim
Summary: Disulfiram and hydralazine have been found to have anti-cancer effects and have been repositioned as adjuvants in cancer therapy. This study evaluated the triple combination of doxorubicin, hydrazine, and disulfiram against wild-type and doxorubicin-resistant MCF-7 breast cancer cells. The results showed that the triple combination reduced drug resistance and enhanced chemosensitivity to doxorubicin in the cancer cells.
Review
Oncology
Katelyn N. Seale, Katherine H. R. Tkaczuk
Summary: Breast cancer management has made significant progress, but it remains a major global health issue. Circulating biomarkers can provide important information on disease progression and treatment response, aiding in treatment decisions.
CLINICAL BREAST CANCER
(2022)
Article
Oncology
Felix Blanc-Durand, Roseline Tang, Margaux Pommier, Marzieh Nashvi, Sophie Cotteret, Catherine Genestie, Audrey Le Formal, Patricia Pautier, Judith Michels, Maria Kfoury, Robert Herve, Sylvie Mengue, Estelle Wafo, Antoine Elies, Gregoire Miailhe, Jennifer Uzan, Etienne Rouleau, Alexandra Leary
Summary: This study investigated the correlation between BRCA1 promoter methylation levels and HRD status and clinical behavior in patients with high-grade ovarian cancer. The results showed that high levels of methylation were positively correlated with HRD status and response to PARPi treatment.
CLINICAL CANCER RESEARCH
(2023)
Review
Medical Laboratory Technology
Timothy Kwang Yong Tay, Puay Hoon Tan
Summary: Liquid biopsies have shown promising results in breast cancer, particularly in monitoring treatment response and predicting disease progression or relapse. With further research and advancements in technology, liquid biopsies may have a greater role in the breast cancer clinic in the future.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2021)
Article
Genetics & Heredity
Oleksii Nikolaienko, Hans P. Eikesdal, Elisabet Ognedal, Bjornar Gilje, Steinar Lundgren, Egil S. Blix, Helge Espelid, Jurgen Geisler, Stephanie Geisler, Emiel A. M. Janssen, Synnove Yndestad, Laura Minsaas, Beryl Leirvaag, Reidun Lillestol, Stian Knappskog, Per E. Lonning
Summary: This study found that approximately 20% of TNBC and low-ER expression breast cancers may be caused by prenatal BRCA1 epimutations. The constitutional mosaic BRCA1 methylation likely arises through gender-related mechanisms in utero, independent of Mendelian inheritance.
Article
Multidisciplinary Sciences
Priscilla Van den Ackerveken, Alison Lobbens, Dorian Pamart, Aristotelis Kotronoulas, Guillaume Rommelaere, Mark Eccleston, Marielle Herzog
Summary: This study found that the levels of H3.1-nucleosomes are elevated in the plasma samples of patients with non-Hodgkin lymphoma (NHL) compared to healthy donors. The study also identified eight histone post-translational modifications (PTMs) that were present at higher levels in NHL patients' plasma. These findings suggest that H3.1-nucleosomes and histone PTMs may serve as useful biomarkers for diagnosing and monitoring non-Hodgkin lymphoma.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Mehdi Manoochehri, Thomas Hielscher, Nasim Borhani, Clarissa Gerhaeuser, Olivia Fletcher, Anthony J. Swerdlow, Yon-Dschun Ko, Hiltrud Brauch, Thomas Bruening, Ute Hamann
Summary: The study found that higher mdNLRs were associated with TNBC, and a lower ratio of NK cells was strongly linked to TNBC. These findings enhance our understanding of the role of the immune system in TNBC and suggest the potential use of NK cell level as a non-invasive molecular marker for TNBC risk assessment, early detection, and prevention.
CLINICAL EPIGENETICS
(2021)
Article
Oncology
Braydon Meyer, Samuel Clifton, Warwick Locke, Phuc-Loi Luu, Qian Du, Dilys Lam, Nicola J. Armstrong, Beena Kumar, Niantao Deng, Kate Harvey, Alex Swarbrick, Vinod Ganju, Susan J. Clark, Ruth Pidsley, Clare Stirzaker
Summary: Neoadjuvant chemotherapy for triple-negative breast cancer requires accurate biomarkers to predict patient response. A study found 9 differentially methylated regions associated with NAC response in TNBC, with 4 of these regions also linked to overall survival. This highlights the potential of DNA methylation biomarkers for predicting NAC response in TNBC.
CLINICAL EPIGENETICS
(2021)
Article
Surgery
Mahesh Sultania, Kamal Kataria, Anurag Srivastava, Mahesh Chandra Misra, Rajinder Parshad, Anita Dhar, Smriti Hari, Sanjay Thulkar
INDIAN JOURNAL OF SURGERY
(2017)
Article
Surgery
Rajinder Parshad, Suhani
INDIAN JOURNAL OF SURGERY
(2017)
Review
Pathology
Prerna Guleria, Nuzhat Husain, Saumya Shukla, Sunil Kumar, Rajinder Parshad, Deepali Jain
ANNALS OF DIAGNOSTIC PATHOLOGY
(2018)
Article
Gastroenterology & Hepatology
Prince Gupta, Rajinder Parshad, Pavithra Balakrishna, Anoop Saraya, Govind K. Makharia, Sanjeev Sachdeva, Raju Sharma
DIGESTIVE DISEASES AND SCIENCES
(2018)
Article
Radiology, Nuclear Medicine & Medical Imaging
Khushbu Agarwal, Uma Sharma, Sandeep Mathur, Vurthaluru Seenu, Rajinder Parshad, Naranamangalam R. Jagannathan
MAGNETIC RESONANCE IMAGING
(2018)
Article
Oncology
Uma Sharma, Khushbu Agarwal, Rani G. Sah, Rajinder Parshad, Vurthaluru Seenu, Sandeep Mathur, Siddhartha D. Gupta, Naranamangalam R. Jagannathan
FRONTIERS IN ONCOLOGY
(2018)
Article
Surgery
Suhani Suhani, Anurag Srivastava, Rajinder Parshad, V. Seenu, Kamal Kataria, Yashvant Rathode
INDIAN JOURNAL OF SURGERY
(2019)
Article
Radiology, Nuclear Medicine & Medical Imaging
Pascal Baltzer, Ritse M. Mann, Mami Iima, Eric E. Sigmund, Paola Clauser, Fiona J. Gilbert, Laura Martincich, Savannah C. Partridge, Andrew Patterson, Katja Pinker, Fabienne Thibault, Julia Camps-Herrero, Denis Le Bihan
EUROPEAN RADIOLOGY
(2020)
Letter
Pathology
Aruna Nambirajan, Rajinder Parshad, Ankur Goyal, N. K. Mithun, Deepali Jain
Article
Surgery
Virinder Kumar Bansal, Mahesh C. Misra, Anil K. Agarwal, J. B. Agrawal, P. N. Agarwal, Sandeep Aggarwal, Mohammad Aslam, Asuri Krishna, Aditya Baksi, Anu Behari, Hemanga K. Bhattacharjee, Rajesh Bhojwani, Jagdish Chander, T. K. Chattopadhyay, Chintamani, Pradeep Chowbey, Abhay Dalvi, N. R. Dash, I. K. Dhawan, Shivanand Gamangatti, P. K. Garg, N. M. Gupta, Rajesh Gupta, S. K. Gupta, Vikas Gupta, L. Kaman, B. M. L. Kapur, Kamal Kataria, Muneer Khan, Ajay K. Khanna, Rajesh Khullar, Anand Kumar, Atin Kumar, Sandeep Kumar, Subodh Kumar, Pawanindra Lal, S. D. Maurya, G. S. Moirangthem, Sujoy Pal, Rajesh Panwar, Rajinder Parshad, Biju Pottakkat, Om Prakash Prajapati, Shailesh Puntambekar, Piyush Ranjan, Yashwant Singh Rathore, Peush Sahni, Rathindra Sarangi, Vuthaluru Seenu, Rajeev Sharma, V. K. Shukla, D. P. Singh, Jaspal Singh, Rajdeep Singh, Rajeev Sinha, Sadiq S. Sikora, Amit Srivastava, Anurag Srivastava, K. N. Srivastava, Shaji Thomas, G. R. Verma, J. D. Wig, V. K. Kapoor
Summary: Cholecystectomy is a common surgical procedure worldwide, with a higher risk of bile duct injury during laparoscopic cholecystectomy. To meet the needs of general surgeons in India, a set of guidelines has been formulated and approved by the SELSI Expert Group.
INDIAN JOURNAL OF SURGERY
(2021)
Article
Surgery
Ajit Singh Oberoi, Rajinder Parshad, Suhani, Vathulru Seenu, Mohit Kumar Joshi, Lokesh Kashyap, Khangembam Jitenkumar Singh
INDIAN JOURNAL OF SURGERY
(2020)
Article
Immunology
Prerna Guleria, Rajinder Parshad, Prabhat Singh Malik, Ruma Ray, R. M. Pandey, Deepali Jain
INDIAN JOURNAL OF MEDICAL RESEARCH
(2019)
Article
Oncology
V. Seenu, Suhani Suhani, Anurag Srivastava, Rajinder Parshad, Sandeep Mathur, Rakesh Kumar
INDIAN JOURNAL OF CANCER
(2019)
Article
Oncology
Tejas Vispute, Suhani, V Seenu, Rajinder Parshad, Smriti Hari, Sanjay Thulkar, Sandeep Mathur
INDIAN JOURNAL OF CANCER
(2018)
Article
Oncology
Suhani, Rajinder Parshad, Mufaddal Kazi, V Seenu, Sandeep Mathur, Siddharth Dattagupta, K. P. Haresh
INDIAN JOURNAL OF CANCER
(2017)
